Drug Discovery and Design, Volume 56

1st Edition

Serial Volume Editors: Edward Scolnick
Hardcover ISBN: 9780120342563
eBook ISBN: 9780080493381
Imprint: Academic Press
Published Date: 9th April 2001
Page Count: 567
185.00 + applicable tax
110.00 + applicable tax
137.00 + applicable tax
161.00 + applicable tax
Unavailable
Compatible Not compatible
VitalSource PC, Mac, iPhone & iPad Amazon Kindle eReader
ePub & PDF Apple & PC desktop. Mobile devices (Apple & Android) Amazon Kindle eReader
Mobi Amazon Kindle eReader Anything else

Institutional Access


Table of Contents

Preface. "Natural History" Clinical Trials: An Enduring Contribution to Modern Medical Practice, E.M. Scolnick, E.E. Slater, and G.W. Williams: Introduction. Role of the Pharmaceutical Industry in Clinical Trials. Use of "Natural History" RCTs to Validate the Cholesterol Hypothesis and Support Changes in the Management of Other Conditions. Development of a New Chemical Entity. "Natural History" RCTs: Some Considerations. Patient Safety. Clinical Trials and the Practice of Medicine in the Age of Genomics. Angiotensin-Converting Enzyme Inhibitors, J. Menard and A. Patchett: Introduction. Peptide Inhibitors. Captopril. Enalapril. Lisinopril. Fosinopril. Clinically Available ACE Inhibitors. Contribution of ACE Inhibitors to the Growth of Physiological and Pathophysiological Knowledge. Biological Advances in the Knowledge of ACE That Evolved in Parallel with the Drug Development Process. Clinical Development Process of ACE Inhibitors in Hypertension. Benefits of ACE Inhibition Beyond the Fall in Blood Pressure. ACE Inhibitors and Congestive Heart Failure. ACE Inhibitors and Myocardial Infarction. ACE Inhibitors, Coronary Heart Disease, and Atherosis. ACE Inhibitors and Prevention of Restenosis. ACE Inhibitors and Renal Insufficiency. The Fallacy of the Concepts of Normotension and Hypertension and the Cardiovascular Protective Effects of ACE Inhibitors. Surrogate End Points in Clinical Trials of ACE Inhibition: Are We Being Misled? Conclusion. HMG-CoA Reductase Inhibitors, R. Illingworth and J.A. Tolbert: Backgr

Description

Strategies to reduce medical uncertainty and build evidence have become critical to the advancement of medical knowledge and modern medical practice. As new techniques and strategies have arisen, so has the need for a current reference work. Drug Discovery and Design examines the latest research in the development of these new strategies. Some of the topics covered include angiotensin converting enzyme inhibitors, HIV protease inhibitors, PPAR agonists for diabetes, and glucan synthase antifungal agents.

Readership

Biochemists, molecular biologists, pharmaceutical and biomedical researchers.


Details

No. of pages:
567
Language:
English
Copyright:
© Academic Press 2001
Published:
Imprint:
Academic Press
eBook ISBN:
9780080493381
Hardcover ISBN:
9780120342563

Reviews

"This volume will be of interest to medicinal chemists, particularly those involved in drug discovery programs. ...Perhaps among the most interesting lessons to be learned from this text is that we are asking a lot from the drug design and discovery process, and that we are very often able to deliver." @source:—-Richard A. Hudson, University of Toledo, in JOURNAL OF MEDICINAL CHEMISTRY (2001) @from:PRAISE FOR THE SERIES @qu:"The authority, originality, and editing of the reviews are first class." @source:—-NATURE @qu:"The Advances in Protein Chemistry series has been a major factor in the education of protein chemists." @source:—-JOURNAL OF THE AMERICAN CHEMICAL SOCIETY


About the Serial Volume Editors

Edward Scolnick Serial Volume Editor

Affiliations and Expertise

Merck and Co., Inc., West Point, Pennsylvania, U.S.A.